Previous close | 106.27 |
Open | 106.00 |
Bid | 107.51 x 1200 |
Ask | 109.88 x 1100 |
Day's range | 105.60 - 109.44 |
52-week range | 62.55 - 113.41 |
Volume | 6,594,042 |
Avg. volume | 7,363,890 |
Market cap | 191.934B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 39.96 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.20 (4.78%) |
Ex-dividend date | 14 Apr 2021 |
1y target est | N/A |
Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. Regeneron Pharmaceuticals' fiscal 2020 performance has been quite remarkable, considering the many pressures it faced due to COVID-19 related restrictions. Regeneron's blockbuster retinal disease drug, EYLEA, continues to be a force to reckon with, clocking sales of $7.9 billion globally (in conjucnction with Bayer).
Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) submitted its 13F-HR regulatory filing to the U.S. Securities and Exchange Commission (SEC) last week. Its activity featured new positions in four stocks and adding to positions in six stocks, including AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Buffett just bought these two dirt-cheap stocks.
Income investors should consider these three high-yield dividend stocks that the market is overlooking right now.